174 related articles for article (PubMed ID: 34616012)
1. Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
Konukiewitz B; Schmitt M; Silva M; Pohl J; Lang C; Steiger K; Halfter K; Engel J; Schlitter AM; Boxberg M; Pfarr N; Wilhelm D; Foersch S; Tschurtschenthaler M; Weichert W; Jesinghaus M
Br J Cancer; 2021 Dec; 125(12):1632-1646. PubMed ID: 34616012
[TBL] [Abstract][Full Text] [Related]
2. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
3. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
4. Simple classifiers for molecular subtypes of colorectal cancer.
Kim WG; Kim JY; Park DY
Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
[TBL] [Abstract][Full Text] [Related]
6. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
7. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
[TBL] [Abstract][Full Text] [Related]
8. Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.
Schmitt M; Silva M; Konukiewitz B; Lang C; Steiger K; Halfter K; Engel J; Jank P; Pfarr N; Wilhelm D; Foersch S; Denkert C; Tschurtschenthaler M; Weichert W; Jesinghaus M
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944797
[TBL] [Abstract][Full Text] [Related]
9. Morphology Matters: A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria From the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases.
Jesinghaus M; Schmitt M; Lang C; Reiser M; Scheiter A; Konukiewitz B; Steiger K; Silva M; Tschurtschenthaler M; Lange S; Foersch S; Becker KF; Saur D; Friess H; Halfter K; Engel J; Boxberg M; Pfarr N; Wilhelm D; Weichert W
Am J Surg Pathol; 2021 Jul; 45(7):969-978. PubMed ID: 34105518
[TBL] [Abstract][Full Text] [Related]
10. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
11. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
Kim JH; Kang GH
World J Gastroenterol; 2014 Apr; 20(15):4230-43. PubMed ID: 24764661
[TBL] [Abstract][Full Text] [Related]
12. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
14. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
17. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival.
Pai RK; Banerjee I; Shivji S; Jain S; Hartman D; Buchanan DD; Jenkins MA; Schaeffer DF; Rosty C; Como J; Phipps AI; Newcomb PA; Burnett-Hartman AN; Le Marchand L; Samadder NJ; Patel B; Swallow C; Lindor NM; Gallinger SJ; Grant RC; Westerling-Bui T; Conner J; Cyr DP; Kirsch R; Pai RK
Gastroenterology; 2022 Dec; 163(6):1531-1546.e8. PubMed ID: 35985511
[TBL] [Abstract][Full Text] [Related]
19. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Mar; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
20. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
